Market Access News | pharmaphorum

News

PHTI backs virtual therapies for musculoskeletal disorders

A new report from the Peterson Health Technology Institute has concluded that many digital therapies for musculoskeletal (MSK) conditions like low back pain can deliver cl

News

FDA panel votes against Lykos’ pioneer psychedelic therapy

FDA independent advisors have comprehensively voted against the use of Lykos Therapeutics’ therapy for post-traumatic stress disorder (PTSD) based on MDMA, also known as e

News

Abbott’s OTC glucose monitor ‘will grow the market’

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM) to be approved by the FDA, Abbott has got the green light for its

News

Moderna gets FDA okay for RSV vaccine mResvia

Moderna has secured FDA approval for its respiratory syncytial virus (RSV) vaccine, giving it a chance to generate revenue from a second product as sales of its Spikevax C

News

Novartis cues up filings for remibrutinib in chronic hives

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – a

News

Dupixent nears EU approval for COPD, as FDA delays

Sanofi and Regeneron’s immunology juggernaut Dupixent is on the brink of another big new indication after it was recommended by the EMA’s human medicines committee for chr

PHTI backs virtual therapies for musculoskeletal disorders

FDA panel votes against Lykos’ pioneer psychedelic therapy

Abbott’s OTC glucose monitor ‘will grow the market’

Moderna gets FDA okay for RSV vaccine mResvia

Novartis cues up filings for remibrutinib in chronic hives

Dupixent nears EU approval for COPD, as FDA delays

Using AI-driven synthetic personas to take your insights fur...

How to meet your physicians where they are online

News

Editor's Picks